Money had been flowing out of this asset since 2012. Harmonic target is below $0 dollars.
Vix is pulling back from 20SMA and may do another Lower Low. If you like my charts useful, please leave me a "like"
TVIX was one of my ideas last week but this week it has retraced almost perfectly to the 61.8% level of the first impulse advance. This is a buy as of next week for a run to $300!!!
I updated the VIX analysis to make it easier to see the 8 day cycle. As you can see, today's drop in the VIX is almost exactly the same as in the past 3 cycles. So, from a cycle/pattern stand point, things are right on track. It felt crazy in the market the last two todays, but I think that has more to do with which stocks are being bought and sold. In addition,...
Stoploss at breakeven. At around 40, look to the equity market for prime short/long positions. I will be looking to add into healthcare today once 38-40 vix handle is met.
This Company engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA . CRSP and Vertex creates new possibilities in medicine to cure diseases and improve people's lives. We work with leading researchers,...
Engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. Shareholders may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term...
A company that designs and develops novel, oral and small-molecule medicines. Its drug candidates include Berotralstat, BCX9930, BCX9250, RAPIVAB, ALPIVAB, RAPIACTA, PERAMIFLU, Galidesivir and Mundesine. anticipates two regulatory approvals for berotralstat in 2020, Even more impressive, that BCRX will likely get a significant near-term boost from the success of...
The company's approach delivers better clinical and financial outcomes while creating a different and better experience for people with chronic conditions. With that, the stock is performing so well that it appears to outdone other sector peers. This would seems to me that this stock may outperform the market over the next one to three months and continue bullish...
See my charts on S&P 500 and VIX for more details. The pattern in the AD line are still holding just like the patterns in the S&P 500 and VIX. There was definitely some "noise" in the AD line, but overall the pattern held.
Order filled at $4.45 (0.886 fib lvl) Stop loss at $3.50 Target at $8.39 (0.618 fib lvl)
Friendly Reminder to All!! ...Well, if you were lucky enough to buy the TVIX before the historic March Market Plunge, and sold it near those highs it produced while most stock markets made their lows, you nailed 1900% gains!!! Also on the 'bargain' priced VXX & VIX = 450% gains!! Enough said. Watch these Volatility Indexes closely, maybe start accumulating...
My long entry from this morning linked below has now been covered, with stoploss at breakeven for a risk free trade going forward. Upside target remains shown in the chart.
Long UVXY, Sold SVXY... the market top is in it seems, I'll gamble some long VIX
TVIX is poised to break significantly higher in the coming weeks. it has retested trendline support and is poised to break out of its wedge.
Trend line has been rejecting the VIX on every dip on the S&P500. If the VIX shoots through the trend line, huge momentum has pushed the S&P through a resistance, and a selloff is incoming.
I see us going up a little bit here and then a lot more. First stop $40.